Search This Blog

Thursday, January 16, 2020

Investors see smoother path for U.S. stocks as Warren’s election odds slip

Traders are less worried about political uncertainty in the run-up to the U.S. presidential election, with former Vice President Joe Biden remaining strong in the polls while Senator Elizabeth Warren has lost ground.

Implied volatility, which measures expectations for outsized equity price moves, has fallen significantly in the past few months for healthcare, financials and energy – sectors considered at risk of disruption or increased regulation under a Democratic president.
The decline in expectations for volatility tracks the poll numbers for Warren, who is considered to be among the most left-leaning Democratic candidates. Warren’s standing peaked in October, according to Reuters/Ipsos polling, and has trailed off since then.
“We were seeing a lot more volatility in September, October, November, when the odds of Elizabeth Warren getting elected were higher,” said Chris Murphy, co-head of derivative strategy at Susquehanna Financial Group. “Joe Biden seems to be the market’s safe candidate.”
Even a boost for Senator Bernie Sanders, another progressive candidate, has had little effect on implied volatility as Biden, seen as a moderate, has maintained a position at or near the lead in several polls.
For instance, 30-day implied volatility for the Health Care Select Sector SPDR Fund has dropped to 12.2% as of Wednesday morning, from 18.9% in early October, according to data from options analytics firm Trade Alert.
“So much of the Iowa anxiety was coming at a time when Warren was trending higher,” said Michael Purves, founder of Tallbacken Capital Advisors in New York, in reference to the Iowa caucuses, the first presidential nominating contest, on Feb. 3. “That anxiety has dissipated.”
Jitters related to the Democratic presidential primaries have not entirely disappeared. CBOE Volatility Index futures expiring in late February show a bump in expectations for volatility. The futures reflect the outlook for the month-long period following that date, which encompasses Super Tuesday on March 3, when several key states, including California and Texas, hold primaries.
Still, “I would expect us to be seeing a lot more Super Tuesday positioning if there was some,” Murphy said.
Both VIX futures and the benchmark S&P 500 U.S. stock index show a significant bump in implied volatility near the Nov. 3 vote, compared to either the preceding or following periods.
“Traders have already started pricing in a hefty election risk premium” around November, wrote Mandy Xu, equity derivatives strategist at Credit Suisse in New York, in a research note on Monday.

Moderna up 6% after CEO interview

Moderna (MRNA +6%) jumps out the gate this morning on the heels of bullish comments from CEO Stephane Bancel on CNBC’s Mad Money with Jim Cramer pertaining to the company’s personalized cancer vaccines.
CMV vaccine candidate, mRNA-1647, poised to advance into Phase 3 development.

Durect shares halted for Ad Com meeting

Nasdaq has suspended trading in DURECT (NASDAQ:DRRX) pending the release of news, in this case, the outcome of an FDA advisory committee meeting today on bupivacaine extended-release solution for post-surgical analgesia.

TG Therapeutics initiates umbralisib application in U.S.

TG Therapeutics (NASDAQ:TGTXlaunches its rolling New Drug Application (NDA) in the U.S. seeking accelerated approval for umbralisib for patients with previously treated marginal zone lymphoma (MZL) and follicular lymphoma (FL). It expects to complete the filing in H1.

Glaxo down 2% in Europe on Barclays cut

GlaxoSmithKline (NYSE:GSK) slips 2% in London after Barclays cut its rating to Underperform with a 1,650 pence (9% downside risk) price target.
Barclays says sales growth this year looks challenging with a slight drop in expected earnings, adding that its multiple myeloma drug may be an also-ran compared to offerings from Celgene and Regeneron Pharmaceuticals.
Its forecast is 57% below the consensus for 2023.
Shares down 1% premarket in the U.S. on light volume.

BioNTech to acquire Neon Therapeutics in all-stock deal

BioNTech SE (NASDAQ:BNTX) has agreed to acquire Neon Therapeutics (NASDAQ:NTGN) in an all-stock transaction valued at ~$67M ($2.18/share). Under the terms of the deal, Neon shareholders will receive 0.063 of a BNTX ADS for each NEON common share held.
Neon’s lead candidate is NEO-PTC-01, a personalized neoantigen-targeted T cell therapy.

FDA OKs ANI Pharma drug for kidney stones

The FDA has approved ANI Pharmaceuticals’ (NASDAQ:ANIP) marketing application for Potassium Citrate Extended-Release Tablets USP, 10 mEq and 15 mEq for the management of renal tubular acidosis with calcium stones (kidney stones), hypocitraturic calcium oxalate nephrolithiasis of any etiology and uric acid lithiasis with or without calcium stones.
Per IQVIA, the U.S. market is ~$75M.